Gliptinaid M 500 Tablet ER
Images are for reference. Actual packaging may vary.
Metformin (500mg) + Teneligliptin (20mg)
1 units • Other
A valid prescription is required for this medicine.
Haven’t found an alternative? A health advisor can help you understand what to do next.
We haven't found a cheaper matching alternative in our catalogue right now. Our health advisors can help you explore other options.
Active composition
+1 more active ingredient
Metformin reduces hepatic glucose production and enhances peripheral insulin sensitivity, lowering blood glucose levels.
Teneligliptin inhibits DPP-4, increasing incretin levels and enhancing insulin secretion.
Medical applications
Gliptinaid M 500 Tablet ER is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, formulated for extended release to provide sustained glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide class agent, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake and utilization.
Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances endogenous incretin hormone levels, thereby increasing insulin secretion and suppressing glucagon release in a glucose-dependent manner. The extended-release formulation ensures a gradual and consistent plasma concentration, improving patient compliance and minimizing gastrointestinal side effects commonly associated with immediate-release metformin.
Gliptinaid M 500 Tablet ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly when monotherapy with metformin or DPP-4 inhibitors is insufficient. It should be used with caution in patients with renal impairment, hepatic dysfunction, or conditions predisposing to lactic acidosis. Regular monitoring of blood glucose levels, renal function, and potential adverse effects is recommended.
This combination therapy offers a complementary mechanism of action, targeting multiple pathophysiological defects in type 2 diabetes for optimal glycemic management.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Side-effect information is not available for this medicine. Please consult your doctor or pharmacist.
Gliptinaid M 500 Tablet ER may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
High Risk
Gliptinaid M 500 Tablet ER is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Medical Advice
Gliptinaid M 500 Tablet ER should be used with caution in patients with kidney disease. Dose adjustment of Gliptinaid M 500 Tablet ER may be needed. Please consult your doctor. Use of Gliptinaid M 500 Tablet ER is, however, not recommended in patients with severe kidney disease. Regular monitoring of kidney function test is advisable while you are taking this medicine.
Exercise Caution
It is not known whether Gliptinaid M 500 Tablet ER alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Consult Doctor
Gliptinaid M 500 Tablet ER is probably unsafe to use in patients with liver disease and should be avoided. Please consult your doctor.
Regular Checkup
0 reviews for Gliptinaid M 500 Tablet ER






